Annual CFF
$221.00 K
+$29.77 M+100.75%
December 31, 2023
Summary
- As of February 8, 2025, SPRO annual cash flow from financing activities is $221.00 thousand, with the most recent change of +$29.77 million (+100.75%) on December 31, 2023.
- During the last 3 years, SPRO annual CFF has fallen by -$130.66 million (-99.83%).
- SPRO annual CFF is now -99.83% below its all-time high of $130.88 million, reached on December 31, 2020.
Performance
SPRO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
NaN%
September 30, 2024
Summary
- As of February 8, 2025, SPRO quarterly cash flow from financing activities is $0.00
- Over the past year, SPRO quarterly CFF has dropped by -$1000.00 (-100.00%).
- SPRO quarterly CFF is now -100.00% below its all-time high of $77.22 million, reached on September 30, 2020.
Performance
SPRO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$1000.00
NaN%
September 30, 2024
Summary
- As of February 8, 2025, SPRO TTM cash flow from financing activities is $1000.00
- Over the past year, SPRO TTM CFF has dropped by -$220.00 thousand (-99.55%).
- SPRO TTM CFF is now -100.00% below its all-time high of $144.38 million, reached on September 30, 2018.
Performance
SPRO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SPRO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +100.8% | -100.0% | -99.5% |
| 3 y3 years | -99.8% | -100.0% | -99.5% |
| 5 y5 years | -99.7% | -100.0% | -99.5% |
SPRO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -99.7% | +100.8% | -100.0% | +100.0% | -100.0% | +100.0% |
| 5 y | 5-year | -99.8% | +100.8% | -100.0% | +100.0% | -100.0% | +100.0% |
| alltime | all time | -99.8% | +100.8% | -100.0% | +100.0% | -100.0% | +100.0% |
Spero Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $1000.00(-99.5%) |
| Dec 2023 | $221.00 K(-100.7%) | $1000.00(-99.5%) | $221.00 K(-98.5%) |
| Sep 2023 | - | $220.00 K(-98.4%) | $14.40 M(-148.7%) |
| Dec 2022 | -$29.55 M(-135.2%) | $14.18 M(+131.3%) | -$29.55 M(-546.6%) |
| Sep 2022 | - | $6.13 M(-111.4%) | $6.62 M(-77.7%) |
| Jun 2022 | - | -$53.68 M(-1507.4%) | $29.71 M(-64.4%) |
| Mar 2022 | - | $3.81 M(-92.4%) | $83.56 M(-0.6%) |
| Dec 2021 | $84.05 M(-35.8%) | $50.35 M(+72.3%) | $84.05 M(+68.8%) |
| Sep 2021 | - | $29.22 M(>+9900.0%) | $49.79 M(-49.1%) |
| Jun 2021 | - | $168.00 K(-96.1%) | $97.78 M(-6.9%) |
| Mar 2021 | - | $4.31 M(-73.2%) | $105.00 M(-19.8%) |
| Dec 2020 | $130.88 M | $16.09 M(-79.2%) | $130.88 M(+8.7%) |
| Sep 2020 | - | $77.22 M(+944.9%) | $120.39 M(+178.8%) |
| Jun 2020 | - | $7.39 M(-75.5%) | $43.19 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $30.19 M(+439.1%) | $44.76 M(+177.3%) |
| Dec 2019 | $16.14 M(-76.8%) | $5.60 M(>+9900.0%) | $16.14 M(+55.7%) |
| Sep 2019 | - | $10.00 K(-99.9%) | $10.36 M(-87.1%) |
| Jun 2019 | - | $8.96 M(+471.6%) | $80.25 M(+12.9%) |
| Mar 2019 | - | $1.57 M(-980.9%) | $71.09 M(+2.3%) |
| Dec 2018 | $69.52 M(-40.1%) | -$178.00 K(-100.3%) | $69.52 M(-51.8%) |
| Sep 2018 | - | $69.90 M(<-9900.0%) | $144.38 M(+94.9%) |
| Jun 2018 | - | -$196.00 K(<-9900.0%) | $74.08 M(+1.3%) |
| Mar 2018 | - | $0.00(-100.0%) | $73.11 M(-37.0%) |
| Dec 2017 | $116.11 M(+237.4%) | $74.68 M(<-9900.0%) | $116.11 M(+180.3%) |
| Sep 2017 | - | -$411.00 K(-64.6%) | $41.43 M(-1.0%) |
| Jun 2017 | - | -$1.16 M(-102.7%) | $41.84 M(-2.7%) |
| Mar 2017 | - | $43.00 M | $43.00 M |
| Dec 2016 | $34.41 M(+125.3%) | - | - |
| Dec 2015 | $15.28 M | - | - |
FAQ
- What is Spero Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Spero Therapeutics?
- What is Spero Therapeutics annual CFF year-on-year change?
- What is Spero Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Spero Therapeutics?
- What is Spero Therapeutics quarterly CFF year-on-year change?
- What is Spero Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Spero Therapeutics?
- What is Spero Therapeutics TTM CFF year-on-year change?
What is Spero Therapeutics annual cash flow from financing activities?
The current annual CFF of SPRO is $221.00 K
What is the all time high annual CFF for Spero Therapeutics?
Spero Therapeutics all-time high annual cash flow from financing activities is $130.88 M
What is Spero Therapeutics annual CFF year-on-year change?
Over the past year, SPRO annual cash flow from financing activities has changed by +$29.77 M (+100.75%)
What is Spero Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SPRO is $0.00
What is the all time high quarterly CFF for Spero Therapeutics?
Spero Therapeutics all-time high quarterly cash flow from financing activities is $77.22 M
What is Spero Therapeutics quarterly CFF year-on-year change?
Over the past year, SPRO quarterly cash flow from financing activities has changed by -$1000.00 (-100.00%)
What is Spero Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SPRO is $1000.00
What is the all time high TTM CFF for Spero Therapeutics?
Spero Therapeutics all-time high TTM cash flow from financing activities is $144.38 M
What is Spero Therapeutics TTM CFF year-on-year change?
Over the past year, SPRO TTM cash flow from financing activities has changed by -$220.00 K (-99.55%)